此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Long-term Follow-up of Actifit® Meniscal Scaffold Patients.

2026年8月31日 更新者:Orteq Sports Medicine

This study will collect retrospective patient data of Actifit patients (medial and lateral, isolated cases as well as cases with concomitant procedures), including pre-op and any post-op imaging, for 120 retrospective Actifit patients, to account for drop-outs and patients refusing a follow-up visit/follow-up imaging.

Each patient without evidence of previous removal of the scaffold, revision to arthroplasty or joint-modifying surgery at the index knee will be contacted by the site, first by phone, to check whether the Actifit device is still in place or not. If no longer in place, patient's situation will be clearly documented, this will preferentially be done via phone or, if necessary, via a prospective visit. If the Actifit is still in place, a prospective follow-up visit will be organised so that patient's current situation can be documented. The prospective follow-up visit may be via an in-person clinic visit (preferred since the visit, provided the patients agrees, includes imaging), telephone or video conference. Any newly occurring events during this prospective visit will also be documented. Of the 120 retrospective patients, we anticipate a group of about 60-100 study participants with the Actifit still in place and being invited to a prospective follow-up visit.

Consent will be requested to collect specific questionnaires (IKDC, KOOS, VAS-pain and, in case available at baseline, Lysholm) and, in case the study participant also agrees to this, an X-Ray/MRI will be collected, provided any previous imaging is > 365 days old.

研究概览

地位

尚未招聘

详细说明

This multicentre study is intended to document the mid- and long-term clinical safety and effectiveness in patients treated with the Actifit meniscus scaffold.

The purpose of this study is to document the mid- and long-term safety and effectiveness of the Actifit Meniscal Scaffold and allow comparisons with other treatment modalities.

Primary Objective:

The primary objective of this study is to collect data to document the safety and effectiveness (IKDC) of the Actifit Meniscal Scaffold at 4-6 years in study participants with an Actifit procedure for the medial or lateral meniscus (isolated or in combination with one or more additional procedures).

Secondary Objectives: The secondary objectives of this study are: 1. To collect safety and effectiveness (IKDC) data on the Actifit Meniscal Scaffold in medial, lateral, isolated or combined procedures at 7-12 years and 12+ years and compare to baseline.2. To collect safety and effectiveness (IKDC) data on the Actifit Meniscal Scaffold in isolated procedures of the medial or lateral meniscus, as well as in pooled isolated and combined procedures at the medial or lateral meniscus at 4-6 years, 7-12 years and 12+ years and compare to baseline.

Additional objectives: 1. To compare VAS, KOOS and, if available, Lysholm preop - to mid- and long-term postoperative outcomes for patients treated with the Actifit® scaffold. 2. To compare preop- (if available) to mid- and long-term postoperative radiographs (baseline to 4-6 years and to the last available radiographs) for patients treated with the Actifit® scaffold. 3. To assess the knee on MRI at mid- and long-term follow-up intervals, if available, and, compare to baseline MRI. 4. To assess (serious) events related to the Actifit device and/or procedure through each of the time points: 4-6 years (this includes any clinically relevant event since the Actifit® operation), 7-12 years and 12+ years.

Two co-primary endpoints in Actifit® procedures at the medial or lateral meniscus (isolated or combined) at 4-6 years of follow-up: 1. Efficacy: the percent improvement in the IKDC from baseline to the 4-6 years follow-up point. 2. Safety/survival: the percentage of study participants at 4-6 years of follow-up, with the device (Actifit®) still in place (not removed); and who did not require conversion to arthroplasty or other joint-modifying surgery (e.g. osteotomy) (Kaplan-Meier survival curves).

Descriptive statistics will be presented for the secondary and additional endpoints below.

Secondary endpoints: Efficacy: Long-term efficacy: IKDC improvement from baseline to 7 - 12 years and 12+ years follow-up in Actifit® procedures (medial or lateral, isolated or combined). Mid- and long-term efficacy: IKDC improvement from baseline to 4-6 years, 7 - 12 years and 12+ years follow-up in Actifit Meniscal Scaffold procedures in isolated procedures of the medial or lateral meniscus, as well as in pooled isolated and combined procedures at the medial or lateral meniscus Safety: Long-term safety/survival (device in place, no joint-modifying surgery) at 7 - 12 years and 12+ years follow-up) in Actifit procedures (medial or lateral, isolated or combined) (Kaplan-Meier survival curves). Mid- and long-term safety/survival (device in place, no joint-modifying surgery) at 4-6 years, 7 - 12 years and 12+ years follow-up of Actifit Meniscal Scaffold procedures in isolated procedures of the medial or lateral meniscus, as well as in pooled isolated and combined procedures at the medial or lateral meniscus, (Kaplan-Meier survival curves).

Additional Endpoints:

Efficacy: Compare preop- to mid- and long-term (4-6, 7-12 years and 12+ years) postoperative outcomes (VAS, KOOS, and, if available, Lysholm) for patients treated with the Actifit scaffold. Compare preop- to mid- and long-term postoperative radiographs for patients treated with the Actifit scaffold (joint space height, Kellgren-Lawrence score, …) at 4-6 years and the last available radiographs (that are > 365 days passed the 4-6 year images). Assess the knee on MRI at long-term follow-up visits: 4-6 and the last available MRI (that is > 365 days passed the 4-6 year MRI), including the WORMS score and other relevant assessments to baseline MRI (contrast or no contrast, before or ≤ 6 months post Actifit procedure) when available. If baseline MRI is not available: assess knee and meniscal condition at long-term follow-up time points.

Safety: Procedure related (serious) events and (serious) device related incidents, side-effects through each of the time points: 4-6 years and since the Actifit operation, 7-12 years and 12+ years.

All endpoints will be analysed separately for adherence to instructions for use, isolated medial or lateral procedures, pooled (isolated and combined) medial or lateral procedures, as well as pooled analyses for the overall cohort (medial, lateral, isolated, combined). Except for the analyses of the overall cohort, the analyses will be exploratory only and will not be used to make claims.

研究类型

观察性的

注册 (估计的)

120

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Lieven Huysse, MD
  • 电话号码:+32 477 96 06 23
  • 邮箱:lhuysse@orteq.com

研究联系人备份

学习地点

    • Oost-Vlaanderen
      • Ghent、Oost-Vlaanderen、比利时、9000
        • University Hospital Gent
        • 接触:
          • Nele Arnout, MD
          • 电话号码:+329332 22 51
          • 邮箱:bws@uzgent.be

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

不

取样方法

非概率样本

研究人群

Patients implanted with an Actifit scaffold more than 4 years ago with the implant still intact and a baseline IKDC score.

描述

Inclusion:

At time of operation, with respect to the involved knee:

  • Patients with irreparable, painful and/or dysfunctional meniscal tissue loss having undergone partial meniscectomy.
  • Sufficient rim over the entire circumference of the meniscus to ensure stable fixation.
  • Well aligned knee joint (varus/valgus <5o) or willing to correct alignment at implant surgery
  • Stable knee joint or ACL deficiencies corrected within 12 weeks after implantation of Actifit.
  • ICRS classification ≤ 3.
  • No more than 3 prior meniscal surgeries on the involved knee.

    • Skeletally mature men or women, aged 16 to 50 years at time of Actifit procedure.
    • Actifit implantation at a minimum of 4 years ago
    • Willing to participate in this long-term follow-up study.

Exclusion:

At time of operation:

  • PCL insufficiency of the involved knee.
  • Significant uncorrected malformations, axial malalignment in the ipsilateral leg.
  • Documented allergy to any of the product components.
  • Systemic or local infection at the time of the operation.
  • Overweight at the time of operation (defined as BMI greater than 35kg/m²)
  • Systemic administration of any type of corticosteroid, antineoplastics, immune-stimulating or immunosuppressive agent within 30 days before or after implantation of Actifit.
  • Evidence of osteonecrosis in the involved knee at the time of the operation.
  • Medical history at time of operation that is positive, for, but not restricted to, the following diseases:

Rheumatoid arthritis Relapsing polychondritis Severe degenerative osteoarthrosis Inflammatory arthritis

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
Patients who have been treated with an Actifit meniscal scaffold
For patients implanted with an Actifit device 4 - 12+ years ago and still have the device in place, consent will be requested to collect specific questionnaires (IKDC, KOOS, VAS-pain) and, in case the study participant also agrees to this, an X-Ray/MRI will be collected, provided any previous imaging is > 365 days old.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Efficacy of the Actifit Meniscal Scaffold
大体时间:4-6 years
The primary objective of this study is to collect data to document the effectiveness (IKDC) of the Actifit Meniscal Scaffold at 4-6 years in study participants with an isolated Actifit procedure for the medial meniscus Description: Effectiveness: For the IKDC. 0 is the worst score and indicates extreme pain and functional limitation. 100 is the best score and indicates no pain and no functional limitation.
4-6 years
Safety of the Actifit Meniscal Scaffold
大体时间:4-6 years
Safety/survival: the percentage of study participants at 4-6 years of follow-up, with the device (Actifit) still in place (not removed); and who did not require conversion to arthroplasty or other joint-modifying surgery (e.g. osteotomy) (Kaplan-Meier survival curves) will be calculated.
4-6 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Clayton Wilson、Orteq Sports Medicine

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2028年9月1日

研究完成 (估计的)

2028年9月1日

研究注册日期

首次提交

2026年7月28日

首先提交符合 QC 标准的

2026年8月31日

首次发布 (实际的)

2026年9月2日

研究记录更新

最后更新发布 (实际的)

2026年9月2日

上次提交的符合 QC 标准的更新

2026年8月31日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅